Lysando AG
Lysando AG is a biopharmaceutical company specialized in antimicrobial protein technologies for combating pathogenic bacteria, particularly resistant and persistent strains. With a core focus on addressing antimicrobial resistance while preserving the human microbiome, the company develops protein-based therapeutic platforms for wound care, dermatology, and broader bacterial infection control. Lysando's solutions aim for effective pathogen management with low risk of resistance development, supporting sustainability and patient-centered healthcare outcomes.
Industries
Nr. of Employees
small (1-50)
Lysando AG
Wangerbergstrasse 91, FL-9497 Triesenberg, Liechtenstein
Lysando AG is currently seeking investment
Lysando AG is seeking a growth-stage investment in the range of 5m-20m
Patents
Products
Topical wound care spray containing engineered antimicrobial proteins, designed to reduce pathogenic bacterial load, promote healing of chronic wounds, and restore skin microbiome balance.
Topical wound care spray containing engineered antimicrobial proteins, designed to reduce pathogenic bacterial load, promote healing of chronic wounds, and restore skin microbiome balance.
Expertise Areas
- Antimicrobial protein engineering
- AI-guided drug discovery
- Microbiome modulation
- Wound care innovation
Key Technologies
- AI-driven protein engineering
- Custom-designed antimicrobial proteins
- Microbiome modulation technology
- Biofilm disruption methods
Key People
Chief Executive Officer
Head of Research & Development
Director of Strategy, Finance and Business Development
Head of Production
Advisory Board Member
Advisory Board Member
Chief Executive Officer
Head of Research & Development
Director of Strategy, Finance and Business Development
Head of Production
Advisory Board Member
Advisory Board Member
News & Updates
Overview and analysis of Lysando’s environmentally friendly antimicrobial platform.
Collaboration yielding new applications for antimicrobial protein technology in animal health.
Study discussing the efficacy of engineered proteins against antibiotic-resistant wound pathogens.
Article discussing next-generation antibacterial strategies following the decline of traditional antibiotics.
Appointment of deep technology and life sciences investment expert Tim McCaffery to Lysando's Advisory Board.
Jorge Cortell, expert in healthcare technology, joins the Advisory Board to contribute towards strategic direction.
Overview and analysis of Lysando’s environmentally friendly antimicrobial platform.
Collaboration yielding new applications for antimicrobial protein technology in animal health.
Study discussing the efficacy of engineered proteins against antibiotic-resistant wound pathogens.
Article discussing next-generation antibacterial strategies following the decline of traditional antibiotics.
Appointment of deep technology and life sciences investment expert Tim McCaffery to Lysando's Advisory Board.
Jorge Cortell, expert in healthcare technology, joins the Advisory Board to contribute towards strategic direction.